SOURCE: Century Capital Markets

September 05, 2012 13:19 ET Highlights Top Traders on the OTC Markets: IFIX, AMPW, BABL, PRTN

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the CENTURY CAPITAL MARKETS

NEW YORK, NY--(Marketwire - Sep 5, 2012) - brings you insight on some of the hottest stocks in the markets. We follow a variety of markets with an emphasis on small and micro-cap companies. We review and search the markets to gain important knowledge that we can pass on exclusively to our subscribers. We are currently tracking IFIX, AMPW, BABL, PRTN.

Internal Fixation Systems, Inc. (OTCQB: IFIX) manufactures and markets orthopedic, spinal and podiatric implants. IFIX focuses on widely used, market proven products used to treat common fractures. IFIX customers include ambulatory surgery centers, hospitals and orthopedic surgeons. IFIX is up 14.29% with a volume of 88,256. For more on IFIX subscribe to

American Power Corporation (OTCQB: AMPW) focuses on the acquisition, exploration, and development of coal, oil, and gas exploration properties in the United States. The company's primary interest is on the Rocky Mountains region. It has certain contractual rights in coal and minerals located in the Judith Basin County, Montana. American Power Corp. was founded in 2007 and is based in Denver, Colorado. AMPW is up 14.29% with a volume of 28,900. For more on AMPW subscribe to

Buildablock Corp. (OTCQB: BABL) is an Internet service platform whose mission is to act as a transactional catalyst between buyers and sellers while leveraging a growing collection of patented, sophisticated user-friendly tools. BABL combines group buying leverage, social media interactivity and automated negotiating tools. BABL is up 15.38% with a volume of 6,000. For more on BABL subscribe to

Pristine Solutions Inc. (OTCQB: PRTN) announced that the Company has entered into an agreement with RoxSan Pharmacy Inc. to provide continued specialized compound prescription of Homatropine in a novel oral suspension ("Tropine 3") to support planned FDA compliant Clinical trial participants. Tropine 3 is a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women. PRTN is up 28.50% with a volume of 14,501,615. For more on PRTN subscribe to

Get information and alerts on IFIX, AMPW, BABL, PRTN and other hot stocks by subscribing at Our alerts and newsletter are always FREE and without obligation.

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid Century Market Research one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.

Contact Information